Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-07-19
2005-07-19
Shameem, Golam M M (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S268100, C546S269100, C546S269700, C546S280400, C546S271400, C546S281700, C548S236000, C514S336000, C514S374000, C514S211010, C514S211150, C540S484000
Reexamination Certificate
active
06919359
ABSTRACT:
The invention provides compounds of Formula I:in-line-formulae description="In-line Formulae" end="lead"?Azabicyclo-N(R1)—C(═X)—W Formula Iin-line-formulae description="In-line Formulae" end="tail"?These compounds may be in the form of pharmaceutical salts or compositions, racemic mixtures, or pure enantiomers thereof. The compounds of Formula I are useful in pharmaceuticals in which α7 is known to be involved.
REFERENCES:
patent: 4605652 (1986-08-01), Welstead, Jr.
patent: 4798829 (1989-01-01), King et al.
patent: 4835162 (1989-05-01), Abood
patent: 4863919 (1989-09-01), Smith
patent: 4988691 (1991-01-01), Benelli et al.
patent: 5017580 (1991-05-01), Naylor et al.
patent: 5025022 (1991-06-01), Naylor et al.
patent: 5039680 (1991-08-01), Impoerato et al.
patent: 5057519 (1991-10-01), Suberg
patent: 5106843 (1992-04-01), Ward et al.
patent: 5175173 (1992-12-01), Sun
patent: 5217975 (1993-06-01), Wadsworth et al.
patent: 5342845 (1994-08-01), Chokai et al.
patent: 5364863 (1994-11-01), Cohen et al.
patent: 5510478 (1996-04-01), Sabb
patent: 5561149 (1996-10-01), Azria et al.
patent: 5624941 (1997-04-01), Barth et al.
patent: 5712270 (1998-01-01), Sabb
patent: 5977144 (1999-11-01), Meyer et al.
patent: 327335 (1988-02-01), None
patent: 378111 (1990-07-01), None
patent: 04-247081 (1992-09-01), None
patent: WO 92/15579 (1992-09-01), None
patent: WO97/30998 (1997-08-01), None
patent: WO98/54189 (1998-12-01), None
patent: WO 00/73431 (2000-12-01), None
patent: WO 01/36417 (2001-05-01), None
patent: WO01/60821 (2001-08-01), None
Bannon, A.W.,American Association for the Advancement of Science. Broad-Spectrum, Non-Opiodid Analgesic Activity by Selective Modulation of Neuronal Nicotinic Acetylcholine Receptors. vol. 279, No 5347, pp. 77-81, 1998.
Holladay, Mark W., et al.,Journal of Medicinal Chemistry. Neuronal Nicotinic Acetylcholine Receptors as Targets for Drug Discovery. Dec. 19, 1997.
Kem, William R.Behavioral Brain Research. “The brain α7 nicotinic receptor may be an important therapeutic target for treatment of Alzheimer's disease: studies with DMXBA (GTS-21).” 113(2000) 169-181.
Macor, JE.Bioorganic&Medicinal Chemistry Letters. “The 5-HT3Antagonist Tropisrtron (ICS 205-930) is a Potent and Selective α7 Nicotinic Receptor Partial Agonist.” 11(2001) 319-321.
Acker Brad A.
Bodnar Alice L.
Groppi, Jr. Vincent E.
Jacobsen Eric Jon
Myers Jason K.
Ebel Eileen M.
Ling Lorraine B.
Pfizer Inc
Richardson Peter C.
Shameem Golam M M
LandOfFree
Azabicyclic-substituted-heteroaryl compounds for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Azabicyclic-substituted-heteroaryl compounds for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Azabicyclic-substituted-heteroaryl compounds for the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3380516